scholarly journals Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)

2021 ◽  
Vol 24 ◽  
pp. 499-508
Author(s):  
Takehiro Kawashiri ◽  
Daisuke Kobayashi ◽  
Mayako Uchida ◽  
Shiori Hiromoto ◽  
Masashi Inoue ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Hematological Malignancies ◽  
Adverse Event Reporting System ◽  
Adverse Event Reporting ◽  
Small Cell ◽  
Secondary Leukemia ◽  
Small Cell Lung ◽  
Odds Ratios ◽  
Endometrial Cancers ◽  
Reporting Rates

Purpose: As the prognosis of cancer patients deteriorates, secondary carcinogenesis after chemotherapy, especially secondary hematological malignancies, becomes a serious problem. However, information on the frequency and time of onset of secondary hematological malignancies and the risk of hematological malignancy with different drugs is scarce. This study aimed to evaluate the incidence of leukemia and myelodysplastic syndrome in patients with solid tumors, including breast, colon, gastric, pancreatic, small cell lung, non-small cell lung, esophageal, ovarian, cervical, and endometrial cancers. Methods: Using the United States Food and Drug Administration Adverse Event Reporting System, we analyzed the reporting rates, reporting odds ratios, and the reporting onset times of secondary leukemia and myelodysplastic syndrome for each drug used. Results: The leukemia reporting rates were higher in breast, small cell lung, ovarian, and endometrial cancers than in other cancers, and the myelodysplastic syndrome reporting rates were higher in ovarian and endometrial cancers than in other cancers. For each cancer type, the reporting odds ratios of cytocidal anticancer agents, such as taxanes, anthracyclines, alkylating agents, platinum, and topoisomerase inhibitors, were higher than those of other drugs. Alternatively, the reporting odds ratios of molecular targeted drugs and immune checkpoint inhibitors were not higher than those of other drugs. Approximately half of the cases of leukemia and myelodysplastic syndrome were reported within 1 to 4 years after chemotherapy. Conclusions: Our study clarified the risks of leukemia and myelodysplastic syndrome for several anticancer drugs in patients with solid tumors. Our data may aid in the assessment of the risks of secondary leukemia and myelodysplastic syndrome when medical oncologists, clinical pharmacists, and patients select chemotherapy regimens.

Secondary myelodysplastic syndrome after small cell lung cancer and esophageal cancer

2005 ◽  
Vol 20 (9) ◽  
pp. 1318-1321 ◽  
Author(s):  
YUICHI OTSUKA ◽  
TOSHIRO KONISHI ◽  
SATOSHI NARA ◽  
KAORU FURUSHIMA ◽  
KENTARO NAKAJIMA ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Esophageal Cancer ◽  
Myelodysplastic Syndrome ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Secondary Myelodysplastic Syndrome

The Prognostic Utility of Log Odds Ratios in Non-Small Cell Lung Cancer (NSCLC)

2013 ◽  
Vol 179 (2) ◽  
pp. 186
Author(s):  
D.M. Thesier ◽  
A. Groman ◽  
P. Prasanna ◽  
M. Hennon ◽  
E. Dexter ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Odds Ratios ◽  
Prognostic Utility ◽  
Log Odds

scholarly journals Secondary Hodgkin Lymphoma and Myelodysplastic Syndrome (MDS) After Paclitaxel-Carboplatin Treatment in a Patient with Small Cell Lung Cancer

PRILOZI ◽  
2017 ◽  
Vol 38 (3) ◽  
pp. 97-103 ◽  
Author(s):  
Marija Petrusevska ◽  
Irina Panovska Stavridis ◽  
Kristina Mladenovska ◽  
Gordana Petrushevska
Keyword(s):  
Lung Cancer ◽  
Myelodysplastic Syndrome ◽  
Small Cell Lung Cancer ◽  
Hodgkin Lymphoma ◽  
Cell Lung Cancer ◽  
Castleman Disease ◽  
Small Cell ◽  
Combined Chemotherapy ◽  
Small Cell Lung ◽  
Secondary Myelodysplastic Syndrome

Abstract Herein synchronous occurrence of Hodgkin lymphoma and secondary myelodysplastic syndrome in a 60 year old male patient with small cell lung cancer treated with combined chemotherapy (carboplatin and paclitaxel) and radiotherapy is presented. The objective of this report is to stress the importance of documenting and monitoring adverse drug reactions that arise from chemotherapy. After four years of treatment with the combined chemotherapy, the patient presented inguinal lymphadenopathy and enlarged lymph nodes and histopathology rapport was suggestive for plasmacytoid variant of Castleman disease. Three years later, biopsy of lymph node was performed and diagnosis of Hodgkin lymphoma – mixed cellularity has been established. Molecular analyses revealed presence of dominant monoclonal population of the immunoglobulin genes in the oligo/monoclonal background. Bone marrow biopsy findings suggested secondary myelodysplasia and revealed signs of hematopoietic cells dismaturation with signs of megaloblastic maturation of the erytropoetic lineage, appearance of ALIP (abnormal localization of immature precursors) in the myeloid lineage and dysplastic megakaryocytes. In addition, an increased level of polyclonal plasmacytes (lambda vs kappa was 60%:40%) was found. Hodgkin lymphoma and MDS occurring after 4 years of carboplatin/paclitaxel therapy might be contributed to the accumulation of alkylator-related DNA damage. This emphasize the need of outlining a monitoring plan regarding development of secondary leukemia and other malignant hematological proliferations should be outlined in the protocols.

Introduction of a Mobile Adverse Event Reporting System Is Associated With Participation in Adverse Event Reporting

2018 ◽  
Vol 34 (1) ◽  
pp. 30-35 ◽  
Author(s):  
Daniel S. Rubin ◽  
Colin Pesyna ◽  
Sharon Jakubczyk ◽  
Chuanhong Liao ◽  
Avery Tung
Keyword(s):  
Adverse Event ◽  
Mobile Application ◽  
Adverse Event Reporting System ◽  
Adverse Event Reporting ◽  
Web Based ◽  
Event Reporting ◽  
The Third ◽  
Time Period ◽  
Wilcoxon Rank Sum Test ◽  
Reporting Rates

Physicians underutilize adverse event reporting systems. Web-based platforms have increased participation; thus, it was hypothesized that a mobile application would increase adverse event reporting. The authors developed a mobile reporting application for iOS and Android operating systems and performed a retrospective review on reporting rates by clinicians in the Department of Anesthesia and Critical Care. Monthly reporting rates were calculated for the intervention year and for the 2 prior years (2013-2016). The Wilcoxon rank sum test and χ2 test were used to evaluate significance. Overall monthly reporting rates for all clinicians were 15.3 ± 7 for the first time period, 17.3 ± 6 for the second time period, and 27.9 ± 7 for the third time period ( P = .0035). The majority of reports in the third time period were submitted using the mobile application (193/337, 57%, P = .026). Deployment of a mobile application reduced barriers to adverse event reporting and increased monthly reporting rates for all clinicians.

Sign in / Sign up

Export Citation Format

Share Document